Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

This trial is testing whether semaglutide — a medication commonly used for type 2 diabetes and weight loss — can prevent or delay the development of full diabetes in women who had gestational diabetes (diabetes during pregnancy) and still show impaired blood sugar levels after giving birth. **You may be eligible if...** - You previously had gestational diabetes diagnosed during weeks 24–32 of pregnancy - You were found to have impaired glucose tolerance (pre-diabetes) 6 to 24 weeks after giving birth - You are not pregnant or breastfeeding and are using effective birth control - You can speak Dutch, French, or English **You may NOT be eligible if...** - You have been diagnosed with type 1 or type 2 diabetes - You have a personal or family history of medullary thyroid cancer or a related genetic syndrome (MEN2) - You have a history of pancreatitis - Your HbA1c was 6.5% or higher during the OGTT in pregnancy (indicating full diabetes) - You are breastfeeding beyond 24 weeks postpartum - You are currently taking medications that significantly affect blood sugar (such as high-dose steroids or metformin) - You have severe kidney disease, heart failure (NYHA class 4), or a serious psychiatric disorder in the past year Talk to your doctor to see if this trial is right for you.